Protein Kinase Inhibitors: New Research pp.167-182
Authors: (Panagiotis Samaras, Frank Stenner - Department of Oncology, Univ. Hospital Zurich, Raemistrasse, Switzerland)
Abstract: Treatment options for cancer have increased in the last years due to the ongoing research and development of new therapeutics. A focus shift from formerly undirected cytostatic agents to more targeted therapies, mainly antibodies and protein kinase inhibitors has taken place. New agents directed against receptors which control proliferation, migration and angiogenesis of tumor cells have been developed. Mainly specific antibodies directed against the extracellular ligand binding domain of various receptor tyrosine kinases, and protein kinase inhibitors targeting the intracellular protein kinase domain of receptors or cytoplasmic signalling proteins have been increasingly developed in the past years. In this chapter we will address the current treatment options with protein kinase inhibitors exemplarily for hepatocellular carcinoma and renal cell cancer. We will further give an insight into the actual research perspectives and the conception of incorporating new drugs into clinical trials as single agent treatment or combined with “classical” chemotherapy. The first part elucidates the molecular pathways of carcinogenesis and depicts the mode of action of these new agents in the treatment of hepatocellular carcinoma, the second part illustrates the pathogenesis of renal cell cancer and the resulting therapeutic options by targeting these pathways.